Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVBIRD: COVID-19 Vaccine Booster in SARDs
NCT05236491Phase 3Unknown
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, open-label trial of NVX-CoV2373 and elasomeran + davesomeran in coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoints: Safety of a booster dose at 28 days and Reactogenicity of a booster dose at 28 days. Status: unknown.
02
Drugs
NVX-CoV2373elasomeran + davesomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05236491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236491.